Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Implantica AG (IMP-A-SDB.ST)
Vaduz, LI
Implantica AG, a medical technology firm established in 2015 and based in Vaduz, Liechtenstein, specializes in the research, development, and commercialization of advanced medical implants. The company focuses on addressing critical, unmet medical needs, primarily conducting its operations and sales in Switzerland. Its flagship offering is RefluxStop, a CE-marked, passive implant designed for the effective prevention of gastroesophageal reflux disease. Implantica is also actively developing a range of other innovative solutions, including e-InVivo, an internal sensor implant capable of monitoring a wide array of health parameters, providing diagnostic data, and facilitating in-body treatment control. The company is also developing a proprietary wireless energizing platform, which serves as a foundation for several remote-controlled devices. These include AppetiteControl, an implant designed to manage obesity by regulating appetite; UriControl, a remote-activated implant for treating urinary incontinence in both men and women; and UriRestor, a remote-controlled device leveraging the wireless platform to enable individuals with spinal cord injuries and multiple sclerosis to urinate on demand. Implantica AG operates as a subsidiary of Implantica MediSwiss.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.48% | +4.35% | +32.20% | +35.65% | +17.29% | +20.70% | +48.57% | +262.37% | -49.27% | -35.38% | -35.38% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+9.1% Q1'26: +12.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-251.9% Q1'26: -529.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-828.6% Q1'26: -392.1% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-929.3% Q1'26: -450.2% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-57.8% Q1'26: -44.5% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-75.5% ★ Q1'26: -75.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.02× Q1'26: -0.02× (vs Q1'25)
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
152.0K
est: 151.5K (+0.3%)
|
387.0K
est: 390.5K (-0.9%)
|
842.0K
est: 947.2K (-11.1%)
|
1.41M
est: 1.28M (+10.1%)
|
1.94M
est: 2.04M (-5.2%)
|
2.11M
est: 2.00M (+5.7%)
|
3.55M
3.55M – 3.55M
+77.7% YoY
|
9.09M
9.09M – 9.09M
+156.2% YoY
|
25.82M
25.82M – 25.82M
+183.9% YoY
|
| EBITDA |
-10.60M
est: -151.5K (-6,898.9%)
|
-13.10M
est: -390.5K (-3,254.4%)
|
-18.39M
est: -947.2K (-1,841.0%)
|
-21.77M
est: -1.28M (-1,602.0%)
|
-25.39M
est: -2.04M (-1,143.5%)
|
-16.78M
est: -2.00M (-739.9%)
|
-3.55M
-3.55M – -3.55M
-77.7% YoY
|
-9.09M
-9.09M – -9.09M
-156.2% YoY
|
-25.82M
-25.82M – -25.82M
-183.9% YoY
|
| EBIT |
-10.64M
est: -151.5K (-6,923.3%)
|
-13.14M
est: -390.5K (-3,265.1%)
|
-18.45M
est: -947.2K (-1,847.5%)
|
-21.84M
est: -1.28M (-1,607.3%)
|
-25.47M
est: -2.04M (-1,147.2%)
|
-19.63M
est: -2.00M (-882.1%)
|
-3.55M
-3.55M – -3.55M
-77.7% YoY
|
-9.09M
-9.09M – -9.09M
-156.2% YoY
|
-25.82M
-25.82M – -25.82M
-183.9% YoY
|
| Net Income |
-10.28M
est: -56.14M (+81.7%)
|
-15.36M
est: -63.94M (+76.0%)
|
-20.82M
est: -106.13M (+80.4%)
|
-23.74M
est: -104.31M (+77.2%)
|
-23.33M
est: -25.80M (+9.6%)
|
-19.99M
est: -20.13M (+0.7%)
|
-22.01M
-22.01M – -22.01M
-9.3% YoY
|
-25.47M
-25.47M – -25.47M
-15.7% YoY
|
-22.79M
-22.79M – -22.79M
+10.5% YoY
|
| SGA |
7.22M
est: 2.86M (+152.9%)
|
5.93M
est: 7.36M (-19.4%)
|
12.22M
est: 17.86M (-31.6%)
|
14.95M
est: 24.12M (-38.0%)
|
12.16M
est: 21.27M (-42.8%)
|
11.26M
est: 20.81M (-45.9%)
|
36.97M
36.97M – 36.97M
+77.7% YoY
|
94.71M
94.71M – 94.71M
+156.2% YoY
|
268.87M
268.87M – 268.87M
+183.9% YoY
|
| EPS |
-0.04
est: -0.20 (+80.3%)
|
-0.05
est: -0.23 (+75.8%)
|
-0.07
est: -0.37 (+80.4%)
|
-0.08
est: -0.37 (+77.2%)
|
-0.08
est: -0.37 (+77.8%)
|
-0.29
est: -0.29 (-0.1%)
|
-0.32
-0.32 – -0.32
-9.3% YoY
|
-0.37
-0.37 – -0.37
-15.7% YoY
|
-0.33
-0.33 – -0.33
+10.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Peter Forsell | Founder & Chief Executive Officer | 208.4K | — |
| Andreas Öhrnberg | Chief Financial Officer | — | male |
| Juanita Eberhart | Vice President of Marketing & Advocacy | — | female |
| Jörg von Manger-Koenig | Company Secretary & Member of Advisory Board | — | male |
| Melanie Houselog | Senior Director & Head of Global QA RA | — | female |
| Nicole Pehrsson | Chief Corporation Affairs Officer | — | female |
| Amit Kukreja | Chief Market Access & Strategy Officer | — | male |
| Stephan Siegenthaler | Chief Strategy Officer & Board Member | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMP-A-SDB.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
